Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Item

http://www.wikidata.org/entity/Q37026878

Q37026878

about

Neuropsychiatric Effects of HIV Antiviral Medications.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.Variation in CYP2A6 Activity and Personalized Medicine.High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

P2860

Q34537705-2234CA35-2742-4631-BA40-7669025200E1 Q37519804-162E5D53-6B90-43A1-80FE-70A19C8B7F62 Q38686531-0440E13F-ABF0-4F4F-B66D-E6DBAA1B6FA1 Q38957969-F8C79E41-5275-46BD-83FA-89AE45C3C224 Q46460183-7EFE89CC-EFF7-4239-A1EB-0D7A4584C867 Q46600089-C0C000D9-54B7-427A-B2E8-11C792335FA1 Q47117336-CA5C9AE1-DD40-4D50-9E7A-C525581E06F2 Q47163198-BB6E2716-B18D-449D-97AF-CC3E66A835B0 Q56910903-BCAD0759-C271-4162-BD61-487561389F78

P2860

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Item

http://www.wikidata.org/entity/Q37026878

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comprehensive Pharmacokinetic, ...... : Results of the ENCORE1 Study

@en

Comprehensive Pharmacokinetic, ...... Results of the ENCORE1 Study.

@nl

type

Item

label

Comprehensive Pharmacokinetic, ...... : Results of the ENCORE1 Study

@en

Comprehensive Pharmacokinetic, ...... Results of the ENCORE1 Study.

@nl

prefLabel

Comprehensive Pharmacokinetic, ...... : Results of the ENCORE1 Study

@en

Comprehensive Pharmacokinetic, ...... Results of the ENCORE1 Study.

@nl

P1476

Comprehensive Pharmacokinetic, ...... : Results of the ENCORE1 Study

@en

P2093

Amanda Clarke

http://www.w3.org/2001/XMLSchema#string

Catherine Orrell

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

David Back

http://www.w3.org/2001/XMLSchema#string

Deirdre Egan

http://www.w3.org/2001/XMLSchema#string

Dianne Carey

http://www.w3.org/2001/XMLSchema#string

Laura Dickinson

http://www.w3.org/2001/XMLSchema#string

Laura Else

http://www.w3.org/2001/XMLSchema#string

Marcelo Losso

http://www.w3.org/2001/XMLSchema#string

Marta Boffito

http://www.w3.org/2001/XMLSchema#string

P2860

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

P2888

s40262-015-0360-5

P304

861-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-015-0360-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288831181

http://www.w3.org/2001/XMLSchema#string

P698

26715213

http://www.w3.org/2001/XMLSchema#string

P932

4916189

http://www.w3.org/2001/XMLSchema#string

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

about

P2860

P2860

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932